This inventor holds 1 USPTO granted patent. Top assignee: Utah Valley University. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Andrew Abell - Innovator in Inhibitor Compounds
Introduction
Andrew Abell is a notable inventor based in Adelaide, Australia. He has made significant contributions to the field of biochemistry, particularly in the development of inhibitor compounds. His innovative work has the potential to impact various therapeutic applications.
Latest Patents
Andrew Abell holds a patent for a composition and method for HIP1-targeting inhibitor compounds. This patent describes an inhibitor compound that targets Hip1, featuring a tripeptide targeting sequence that directs the compound to the active site of Hip1. Additionally, the compound includes a C-terminal electrophilic warhead conjugated to the targeting sequence, which is designed to inactivate the enzyme.
Career Highlights
Andrew Abell is affiliated with Utah Valley University, where he continues to advance his research and innovation in the field. His work is characterized by a commitment to developing novel compounds that can lead to significant advancements in medical science.
Collaborations
Throughout his career, Andrew has collaborated with esteemed colleagues such as Nathan E Goldfarb and Nicholas Schumann. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions.
Conclusion
In summary, Andrew Abell is a distinguished inventor whose work on HIP1-targeting inhibitor compounds showcases his dedication to advancing biochemistry. His contributions are poised to make a lasting impact in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile